Vancomycin update - School of Medicine | School of Medicine
Transcript of Vancomycin update - School of Medicine | School of Medicine
![Page 1: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/1.jpg)
Vancomycin update
ECHO
Antibiotic Stewardship Program
Charles Krasner, M.D.
August 16, 2018
.
.
![Page 2: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/2.jpg)
Vancomycin blocks
bacterial cell wall
production
.
.
![Page 3: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/3.jpg)
Cell wall of gram positive
bacteria disrupted by vancomycin
.
.
![Page 4: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/4.jpg)
Gram positive cocci in clusters
(Staph) and in cha
.
.
![Page 5: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/5.jpg)
Only effective
against gram bacteria
.
.
![Page 6: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/6.jpg)
Active in a wide variety of infections
.
.
![Page 7: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/7.jpg)
Histamine release causes
transient itchy rash
.
.
![Page 8: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/8.jpg)
Red Man urticarial Rash
NOT a true allergy- slow
infusion down!
.
.
![Page 9: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/9.jpg)
Can also get a typical drug rash with vancomycin -usually not urticarial in
appearance and doesn’t resolve quickly with anti-
histamines. Do not re-challenge these patients!
.
.
![Page 10: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/10.jpg)
Some studies have suggested nephrotoxicity
related to Vancomycin trough levels
.
.
![Page 11: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/11.jpg)
“Nephrotoxicity during Vancomycin therapy in combination with Pip-Tazobactam or Cefepime” Rutter,W.C. et al. Antimicrob. Agents Chemother: Feb 2017 Univ Kentucky Healthcare
• 4,193 patients - retrospective, matched cohort study over 4 year period (2010-4). Did not include patients on dialysis, preg, CKD, cystic fibrosis.
• When patients were matched on multiple factors-age, sex, contrast exposure, severity of illness, trough concentrations and multiple other confounding factors:
• Adjusted AKI – Zosyn/vanco- 21.4 %• Adjusted AKI- Cefep/vanco – 12.6%
(P.<0001)• “reinforces the need for judicious use of
combination empirical anti-microbial therapy”
.
.
![Page 12: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/12.jpg)
Consequences of vancomycin toxicity
• Studies have demonstrated:• increased LOS in patients with acute
kidney injury (AKI) in patients with MRSA bacteremia compared to those without AKI (20 versus 13 days)
• longer time in ICU in those with AKI than those without(17 days versus 12 days)
• Slight increased risk of needing hemodialysis in AKI patients
• Increased hospital costs in AKI- LOS, dialysis, etc
.
.
![Page 13: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/13.jpg)
“Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes” W.E. Self et al Clinical Inf Diseases May, 2016
• Vanderbilt University study that looked at prevalence of MRSA pneumonia in CAP patients (eliminated most HCAP type patients- recent hosp, dialysis, cancer, SNF etc) in 5 hospitals over 2 ½ year period
• 2259 patients
• Approx 30%of patients received initial anti-MRSA antibiotics – (vancomycin or linezolid)
• 1.6% had Staph aureus or MRSA pna- only 0.9% had MRSA
• If admitted to ICU- 2.7% had MRSA
• If admitted to floor only 0.1% had MRSA!
• Bottom line- only 1 of 30 patients given empiric MRSA coverage for CAP actually had MRSA
• If a CAP patient is not sick enough for ICU, very unlikely to have MRSA pneumonia
.
.
![Page 14: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/14.jpg)
Cellulitis case
67 year old overweight ,diabetic male admitted with cellulitis and severe sepsis.
Has hx of peripheral vascular disease, neuropathy and ulcers on his feet. Seeing wound care at hospital clinic
Develops confusion , fever, rapidly progressive rash moving up leg.
Febrile to 102 F, HR112 and BP 100/68
.
.
![Page 15: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/15.jpg)
ER physician starts vancomycin and pip/tazobactam
(Zosyn) for severe sepsis diagnosis
.
.
![Page 16: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/16.jpg)
If cultures are negative for MRSA-stop the
vancomycin!
.
.
![Page 17: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/17.jpg)
Spell out in your sputum culture result
there is no MRSA present
.
.
![Page 18: Vancomycin update - School of Medicine | School of Medicine](https://reader030.fdocuments.us/reader030/viewer/2022020916/61a82e0611c87520b42e9ef4/html5/thumbnails/18.jpg)
A few pointers to reduce vancomycin use
• A patient with CAP who isn’t in the ICU, isn’t spiking high feversand doesn’t have cavities on CXR, is very unlikely to have MRSApneumonia. Go with IDSA guidelines – ceftriaxone/azithromycinor doxycycline . Don’t use empiric vancomycin for thesepatients.
• If in ICU with pneumonia, and blood and sputum cultures donot show MRSA after 48 hours- stop the vancomycin. Theydon’t have MRSA pneumonia
• Don’t use vancomycin for non-purulent cellulitis- almostcertainly strep. Try cefazolin, amp-sulbactam or simplyampicillin iv
• Remember ECHO talk on pseudo-cellulitis- 40% of “cellulitis”cases are not infectious- particularly if no fever and bilateral
• Try not to use vanco/zosyn- too high risk for nephrotoxicity
.
.